
-
Recursion Pharmaceuticals NASDAQ:RXRX Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.
Location: | Website: www.recursionpharma.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.725B
Cash
594.4M
Avg Qtr Burn
-89.79M
Short % of Float
23.13%
Insider Ownership
3.57%
Institutional Own.
77.45%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REC-2282 Details Neurofibromatosis Type 2-mutated meningiomas | Phase 2/3 Update | |
REC-3964 Details Clostridium difficile Colitis | Phase 2 Data readout | |
REC-4881 Details Cancer | Phase 2 Data readout | |
REC-4881 Details Familial Adenomatous Polyposis | Phase 2 Data readout | |
REC-994 Details Cerebral cavernous malformation | Phase 2 Update | |
REC-1245 Details Cancer | Phase 1/2 Data readout | |
REC-4539 Details Small cell lung cancer, Cancer | Phase 1/2 Initiation | |
REC-3565 Details R/R B-cell Lymphoma | Phase 1 Data readout | |
REC-617 Details Solid tumor/s, Cancer | Phase 1 Update | |
REC-3599 Details GM2 gangliosidosis | Failed Discontinued |